Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HENLIUS (02696.HK) HLX15-SC Completes First Patient Dosing in China for International Multi-center Phase 1 Trial in NDMM
Recommend 3 Positive 1 Negative 0 |
||||
|
||||
|
HENLIUS (02696.HK) announced that HLX15-SC (recombinant anti-CD38 fully human monoclonal antibody injection for subcutaneous injection) (HLX15-SC) has recently completed the first patient dosing in China (excluding Hong Kong, Macau and Taiwan regions of China) for its international multi-center Phase 1 clinical study as a first-line treatment for newly diagnosed multiple myeloma (NDMM). The primary objective of the study is to compare the pharmacokinetic (PK) similarity between HLX15-SC and the reference drug after single and multiple subcutaneous (SC) injections in target patients. Secondary objectives include comparing the PK characteristics, safety, tolerability, immunogenicity and efficacy between HLX15-SC and the reference drug following single and multiple SC injections. (sl/u) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
